A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma.
Younes
Anas
A
Section of Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, TX, USA. ayounes@mdanderson.org
D000951:Antigens, Neoplasm / Q000276:immunology* / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006360:Heat-Shock Proteins / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D013997:Time Factors
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; C052646:sarcoma glycoprotein gp96 rejection antigens; C484813:vitespin